Article

Balloon kyphoplasty better for vertebral compression fracture

Balloon kyphoplasty results in more and faster improvements in quality of life and disability measures and reduction of back pain than nonsurgical treatment for patients with acute painful vertebral fracture. However, the differences in improvement diminish by 1 year after treatment for most outcome measures, probably because of natural fracture healing.

Balloon kyphoplasty results in more and faster improvements in quality of life and disability measures and reduction of back pain than nonsurgical treatment for patients with acute painful vertebral fracture. However, the differences in improvement diminish by 1 year after treatment for most outcome measures, probably because of natural fracture healing.

Wardlaw and associates randomized 300 patients who had 1 to 3 significant compression fractures to balloon kyphoplasty or nonsurgical care. The primary study outcome was the difference in the Short Form-36 (SF-36) physical component summary (PCS) score between baseline and 1 month.

The SF-36 PCS score was 5.2 points better in the kyphoplasty group than in the nonsurgical group during the first month; it remained about 3.5 points better over the year. Surgical patients also enjoyed better quality of life, had less body pain and greater physical vitality, and could function better socially. Although they also reported 2.9 fewer days of disability than the nonsurgical group during the first postoperative month, this difference diminished by 12 months.

The authors noted that their findings will help inform decisions about the use of balloon kyphoplasty as an early treatment option for patients with vertebral compression fracture.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.